Drug intelligence / Profile preview

PF-08046033

Development stage: Phase 1
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PF-08046033 is an investigational monoclonal antibody developed by Pfizer that targets P-selectin glycoprotein ligand-1 (PSGL-1), also known as SELPLG. PSGL-1 is an immune checkpoint regulator expressed on various immune cells, including T cells and myeloid cells, where it plays a role in modulating immune responses within the tumor microenvironment. By binding to PSGL-1, PF-08046033 aims to reverse immune exhaustion and promote an anti-tumor immune response. It is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), and melanoma.

Targets

PSGL-1 (P-selectin glycoprotein ligand-1)

Beyond the preview

Go deeper on PF-08046033.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-08046033.

Explore the full profile